TScan Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell TCRX and other ETFs, options, and stocks.About TCRX
TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. Its platform identifies previously uncharacterized, clinically-derived shared T cell antigens and all off-target TCR interactions, to enable the development of efficacious TCR-Ts.
CEOGavin MacBeath
CEOGavin MacBeath
Employees194
Employees194
HeadquartersWaltham, Massachusetts
HeadquartersWaltham, Massachusetts
Founded2018
Founded2018
Employees194
Employees194
TCRX Key Statistics
Market cap58.17M
Market cap58.17M
Price-Earnings ratio-0.91
Price-Earnings ratio-0.91
Dividend yield—
Dividend yield—
Average volume638.42K
Average volume638.42K
High today$1.04
High today$1.04
Low today$0.98
Low today$0.98
Open price$1.00
Open price$1.00
Volume348.20K
Volume348.20K
52 Week high$3.21
52 Week high$3.21
52 Week low$0.8824
52 Week low$0.8824
Stock Snapshot
As of today, TScan Therapeutics(TCRX) shares are valued at $1.03. The company's market cap stands at 58.17M, with a P/E ratio of -0.91.
During the trading session on 2026-01-04, TScan Therapeutics(TCRX) shares reached a daily high of $1.04 and a low of $0.98. At a current price of $1.03, the stock is +5.1% higher than the low and still -1.0% under the high.
Trading volume for TScan Therapeutics(TCRX) stock has reached 348.2K, versus its average volume of 638.42K.
The stock's 52-week range extends from a low of $0.88 to a high of $3.21.
The stock's 52-week range extends from a low of $0.88 to a high of $3.21.
Analyst ratings
71%
of 7 ratingsBuy
71.4%
Hold
28.6%
Sell
0%
People also own
Based on the portfolios of people who own TCRX. This list is generated using Robinhood data, and it’s not a recommendation.